Erika Hamilton, MD - How to Harness Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast Cancer: New Goals and Better Tools to Close the Gaps

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/WFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the last two decades, there have been very limited advancements in the treatment of HR+, HER2- early breast cancer, and a particularly marked unmet need has existed for patients at the highest risk of recurrence. Fortunately, there is new hope of improved outcomes for these patients following the recent FDA approval of the first CDK4 and 6 inhibitor for the adjuvant treatment of patients with HR+, HER2-, node+ early breast cancer at high risk of recurrence and a Ki-67 score ≥20%. Shortly thereafter, guideline updates were released that recommended adjuvant CDK4 and 6 inhibitor therapy combined with endocrine therapy to a broader population of patients at high risk of recurrence. The emergence of this new therapeutic option along with varied indications and recommendations has resulted in much uncertainty about which patients should and should not receive adjuvant CDK4 and 6 inhibitor therapy, and how to best integrate it into clinical practice to meaningfully impact outcomes in this challenging patient population. In this educational activity, two leading experts deliver pertinent updates and use patient cases to provide practical guidance for the multidisciplinary team on how to navigate the changing standards of care in HR+, HER2- early breast cancer. Learn how to identify the most appropriate patients who can achieve the highest absolute benefit from adjuvant CDK4 and 6 inhibition, and ensure that those with a particularly poor prognosis are not excluded from this therapy. Additionally, receive guidance on how to recognize and manage treatment-related adverse events so that patients continue to adhere to CDK4 and 6 inhibitor therapy and derive maximum benefit from it in the adjuvant setting. Upon completion of this activity, participants should be better able to: Discuss the evidence, tools, and strategies for risk assessment and stratification in HR+, HER2- early breast cancer to guide treatment selection, including identification of candidates for adjuvant CDK4 and 6 inhibitor therapy, Integrate the latest safety and efficacy data on adjuvant CDK4 and 6 inhibitor therapy into clinical decisions for patients with high-risk, HR+, HER2- early breast cancer, Incorporate modern risk assessment approaches, supporting evidence, regulatory and guideline recommendations, adverse event prevention/management strategies, and shared decision-making into the establishment of individualized treatment plans for patients with HR+, HER2- early breast cancer to improve outcomes in this patient population, including reducing the risk of recurrence in patients with poor prognosis.